The WHO declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo a public health emergency of international concern (PHEIC) as case counts and suspected clusters rose and spread beyond initial focus areas. The announcement followed laboratory-confirmed cases and growing suspicion of underdetection, with the WHO citing significant uncertainty about the true scale. For the biotech pipeline, the declaration renews attention on countermeasure readiness against non-Zaire Ebola strains, including vaccine development efforts noted as not yet available and antiviral gaps where licensed products do not exist for this species. Separately, reporting highlighted that vaccines targeting Bundibugyo are under development but none are ready yet, setting the stage for accelerated clinical trial planning and further procurement discussions as containment efforts continue.